Sign In
Buy PBM
$3.95
+0 (+0%)
At Close: Jun 03, 2026
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
09:15am, Friday, 15'th May 2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-de
Pacific Bay Adopts Semi-Annual Reporting
08:43pm, Monday, 04'th May 2026
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or the "Company") reports that the Company is adopting semi-annual financial reportin
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
07:00am, Thursday, 23'rd Apr 2026
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-comp
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
10:33am, Monday, 20'th Apr 2026
Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
07:42am, Monday, 20'th Apr 2026
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
07:42am, Monday, 20'th Apr 2026
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain Through its investment in and collaboration with PsyLabs, the C
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
09:15am, Friday, 17'th Apr 2026
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethic
Aurwest Resources Announces Execution of Definitive Agreement on Weaver Lake Gold Project
01:00pm, Tuesday, 14'th Apr 2026
Calgary, Alberta – TheNewswire - April 14, 2026 – Aurwest Resources Corporation (“ Aurwest ” or the “ Company ”) ( CSE: AWR ) is pleased to announce that the Company has entered into a Def
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
09:15am, Wednesday, 08'th Apr 2026
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibog
Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)
02:14am, Thursday, 19'th Mar 2026
Psyence Biomedical (NASDAQ: PBM - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
09:15am, Wednesday, 11'th Mar 2026
“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig “The strongest companies are built on the right foundations long before th
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
09:15am, Tuesday, 03'rd Mar 2026
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibog
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
05:20pm, Friday, 20'th Feb 2026
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
09:15am, Tuesday, 17'th Feb 2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
06:30pm, Friday, 13'th Feb 2026
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby secu
